MedTrace Logo

UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma

NCT07500805 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-03-30

No results posted yet for this study

Summary

This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of UCL70805F in patients with CD70-positive advanced renal clear cell carcinoma.

Conditions

  • CD70-positive Advanced Renal Clear Cell Carcinoma

Interventions

BIOLOGICAL

UCL70805F

D0: 5×10\^4 cells ～ 4×10\^5 cells

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • UTC Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Yi Zhang · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2028-05-01
Completion
2029-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07500805 on ClinicalTrials.gov